Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XSpray Pharma ABSTU:6XP -3.43%28 Debt-to-Equity is 0.23 as of Jun. 2026, which is 1050% above its 10-year median of 0.02. GuruFocus rates STU:6XP with a GF Score™ of 28/100. Among 966 Biotechnology companies, XSpray Pharma AB ranks worse than 58.49% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for XSpray Pharma AB's Debt-to-Equity or its related term are showing as below:
STU:6XP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.26
Current: 0.23
During the past 9 years, the highest Debt-to-Equity Ratio of XSpray Pharma AB was 0.26. The lowest was 0.00. And the median was 0.02.
STU:6XP's Debt-to-Equity is ranked worse than 58.49% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs STU:6XP: 0.23
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
XSpray Pharma AB Debt-to-Equity Related Terms
XSpray Pharma AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for XSpray Pharma AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6XP vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, XSpray Pharma AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XSpray Pharma AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where XSpray Pharma AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSpray Pharma AB (STU:6XP) has a Debt-to-Equity of 0.23 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on XSpray Pharma AB and its competitors. This is 1050% above median its historical median of 0.02. According to the industry distribution chart, XSpray Pharma AB ranks #565 out of 966 companies in the Biotechnology industry, placing it in the top 58.5%.
Is XSpray Pharma AB's Debt-to-Equity too high?
XSpray Pharma AB's current Debt-to-Equity of 0.23 is 1050% above median its 10-year median of 0.02. The Biotechnology industry median Debt-to-Equity is 0.15. XSpray Pharma AB's value of 0.23 is 53.3% above this industry median. Based on the distribution chart, XSpray Pharma AB ranks #565 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, XSpray Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XSpray Pharma AB ranks #565 out of 966 companies for Debt-to-Equity. This places XSpray Pharma AB in the lower half of its industry. The industry median Debt-to-Equity is 0.15. XSpray Pharma AB's value of 0.23 is 53.3% above this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.15, XSpray Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XSpray Pharma AB's current Debt-to-Equity of 0.23 is 53.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on XSpray Pharma AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XSpray Pharma AB's current Debt-to-Equity is 0.23, which is 1050% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (STU:6XP) has a current Debt-to-Equity of 0.23. The current Debt-to-Equity is 0.23, which is 1050% above median its 10-year median of 0.02 and 53.3% above the Biotechnology industry median of 0.15. XSpray Pharma AB's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For XSpray Pharma AB (STU:6XP), the current Debt-to-Equity is 0.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
28GF Score
Get the complete analysis for STU:6XP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6XP has been successfully added to your 
